- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Mi | UK cell therapy biotech lays off 25% of staff, turns to tool development over therapeutics | ||
| Mi | Flatiron Health irons out pact to bring data capture tech to National Cancer Institute trial sites | ||
| Mi | Dexcom survey shows healthcare providers opt for CGM tech over new medications in Type 2 diabetes | ||
| Mi | Synchron and Nvidia set sights on AI model trained by direct brain activity | ||
| Mi | Immunovant won't seek approval for autoimmune drug despite phase 3 win | ||
| Mi | Servier pays $70M to polish Black Diamond's deprioritized solid tumor prospect | ||
| Mi | Roche continues ADC dealmaking spree with $1B biobucks pact with Oxford BioTherapeutics | ||
| 18.03. | Director of NIH's National Human Genome Research Institute departs: Stat | ||
| 18.03. | Quest Diagnostics teams up with Google Cloud for gen AI customer service | ||
| 18.03. | Flagship's Empress lays off 53% of staffers in push to get science to clinic | ||
| 18.03. | Sequel Med Tech connects twiist insulin pump to Abbott's CGM ahead of market debut | ||
| 18.03. | Arch-backed HC Bioscience closes doors after seeing early data for tRNA asset | ||
| 18.03. | Vincerx, left in limbo by collapsed deal, moves to merge with AI company to escape cash crisis | ||
| 18.03. | Pyxis lays off 20% of staff to swing behind single-candidate strategy | ||
| 18.03. | Kiromic furloughs 'substantially all' workers amid cash crunch, leaving 31 staff without pay | ||
| 18.03. | Nanobiotix tweaks J&J licensing deal for phase 3 cancer drug to eke out cash | ||
| 17.03. | Avidity's latest DMD data drop assuages safety concerns for RNA-based asset: analyst | ||
| 17.03. | Flagship-backed Apriori Bio lays off employees, shifts focus to pipeline development | ||
| 17.03. | Avanos taps Siemens Healthineers' Americas president as CEO | ||
| 17.03. | Curevo rounds up $110M to challenge GSK's Shringrix, nabs Moncef Slaoui to lead board | ||
| 17.03. | FDA warns hemodialysis tubing shortage could continue into autumn | ||
| 17.03. | Opko, Entera share ownership of first oral GLP-1/glucagon agonist set to enter clinic | ||
| 17.03. | Incyte posts phase 3 skin condition wins but details disappoint, sinking stock | ||
| 17.03. | Otsuka's Taiho pays $400M for Swiss partner to 'turbocharge' 3 ADCs to clinic | ||
| 17.03. | AstraZeneca goes in vivo, penning $1B deal for Belgian off-the-shelf cell therapy biotech |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
